Insights & news

European Commission Presents EU4Health Programme

  • 29/05/2020
  • Articles

On 28 May 2020 the European Commission (the Commission) presented details of its new, stand-alone EU4Health Programme, a proposal to commit considerable EU resources to health during the 2021-2027 period (EU4Health). The budget which the Commission proposes to earmark for EU4Health, EUR 9.4 billion, reflects a more than 20-fold increase over the funds previously dedicated to this policy area (EUR 413 million). The Commission first made its plan public as part of the presentation of ‘Next Generation EU’, a EURO 750 billion recovery plan to be embedded in and added to the long term overall EU budget for the 2021-2027 period (see, Van Bael & Bellis Life Sciences News Alert, 28 May 2020).

As Article 3 of the Commission’s proposed EU4Health Regulation indicates, EU4Health has three objectives:

  1. protecting people in the EU from serious cross-border health threats and improving crisis management capacity;
  2. making medicines, medical devices and other crisis relevant products, available and affordable while supporting innovation;
  3. trengthening health systems and the health care workforce.

While the scope of EU4Health is clearly designed to tackle the fall-out of the Covid-19 crisis, the programme will also address longer-term health challenges. Concretely, under EU4Health the following action points will be envisaged:

  1. strengthening the capability of preventing and responding to serious cross-border threats to health and managing health crises;
  2. creating stockpiles of crisis relevant products and a reserve of medical, healthcare and support staff that can be mobilised in case of a crisis;
  3. supporting actions to ensure the availability and affordability of crisis relevant products and other health supplies;
  4. reinforcing the accessibility and resilience of health systems by supporting digital transformation, implementing new care models and addressing inequalities in health;
  5. focusing on the surveillance, prevention, diagnosis and treatment of non-communicable diseases such as cancer;
  6. supporting the prudent and efficient use of medicines, including antimicrobials, and reinforcing the more environmentally friendly production and disposal of medicines and medical devices;
  7. developing, implementing and enforcing Union health legislation and providing reliable data to underpin policy making and monitoring and promoting the use of health impact assessments of proposed policies;
  8. supporting integrated work among Member States.

A Commission press release on the subject as well as the Commission’s proposed EU4Health Regulation are attached.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 13/07/2020
    • Articles

    Competition Developments in Pharmaceutical Sector - UK Competition and Markets Authority and European Commission

    The pharmaceutical sector continues to draw competition scrutiny across Europe. United Kingdom On 9 June 2020, the Competition and Markets Authority (CMA) concluded its investigation into the supply of fludrocortisone acetate tablets (FAT), a prescription-only medicine indicated for the treatment of primary and secondary adrenal insufficiency, known as Addison’s Disease (see, attached press release). Aspen Pharma (Aspen) of South-Africa, UK based company Amilco and Dutch firm Tiofarma had apparently agreed that Aspen would be the sole supplier of FAT in the UK. Amilco and Tiofarma were promised financial compensation, while Aspen was given free rein which allegedly allowed it to abuse its monopoly position and increase its prices for FAT by up to 1,800%.

    Read more
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *